Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda’s/Sucampo Amitiza Gains IBS-C Indication

This article was originally published in PharmAsia News

Executive Summary

Takeda/Sucampo Pharmaceuticals' chronic idiopathic constipation drug Amitiza (lubiprostone) was approved by FDA April 29 for irritable bowel syndrome with constipation in women 18 years and older, making it the only drug available for IBS-C with a prescription

You may also be interested in...

Sucampo Releases Positive Phase III Data For Amitiza In Japan

TOKYO - Sucampo's chronic idiopathic constipation treatment Amitiza (lubiprostone) may soon have a chance at a second life in a new market after the company announced positive results of a pivotal Phase III trial in Japanese patients

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts